Transgenic constructs for studying fibrotic diseases and uses thereof
OwnerMichael Breindl, David A. Brennerinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a reporter gene to study the tissue-specific expression of certain genes associated with fibrotic disease. More particularly, it relates to transgenic nucleic acid constructs having the reporter gene under operational control of the Collal promoter further comprising a regulatory element that regulates the expression of collagen. Such constructs and methods using these constructs are particularly useful in studying correct stage and tissue specific expression of collagen.
Claims18
A transgenic nucleic acid construct useful for assessing collagen production associated with fibrotic disease, wherein said construct comprises nucleic acid sequences encoding:
- a) a Colla1 gene-specific regulatory element, wherein said regulatory element is associated with correct stage or tissue specific expression of collagen, and wherein said regulatory element is inserted into the construct at a far upstream DNAse I-hypersensitive site;
- b) a Colla1 gene promoter;
- and
- c) a reporter.
A transgenic nucleic acid construct useful for assessing collagen production associated with fibrotic disease, wherein said construct comprises nucleic acid sequences encoding:
- a) a Colla1 gene-specific regulatory element, wherein said regulatory element is inserted into the construct at a far upstream DNAse I-hypersensitive site, and wherein the regulatory element is steroid hormone-dependent;
- b) a Colla1 gene promoter;
- and
- c) a reporter.
A method for assessing collagen production associated with fibrotic disease, comprising:
- a) constructing a transgenic nucleic acid construct, wherein said construct comprises nucleic acid sequences encoding:
- i) a Colla1 gene-specific regulatory element, wherein said regulatory element is inserted into the construct at a far upstream DNAse I-hypersensitive site;
- ii) a Colla1 gene promoter;
- and
- iii) a reporter;
- and
- b) transfecting the construct into a cell or non-human animal capable of expressing the reporter;
- and
- c) monitoring expression in said cell or non-human animal under varying conditions.
The method according to claim 22, wherein the fibrotic disease is polycystic ovarian syndrome.
The method according to claim 22, wherein the fibrotic disease is uterine leiomyomas.
The method according to claim 22, wherein the fibrotic disease is cardiac fibrosis.
The method according to claim 22, wherein the fibrotic disease is myocardial infarction-initiated.
A method for assessing collagen production during different stages of embryotic development, comprising:
- a) constructing a transgenic nucleic acid construct, wherein said construct comprises nucleic acid sequences encoding:
- i) a Colla1 gene-specific regulatory element, and wherein said regulatory element is inserted into the construct at a far upstream DNAse I-hypersensitive site;
- ii) a Colla1 gene promoter;
- and
- iii) a reporter;
- b) transfecting the construct into a non-human animal capable of expressing the reporter during different stages of embryotic development;
- and
- c) monitoring expression in said non-human animal during different stages of embryonic development.
A method for assessing differential collagen production in different tissues, comprising:
- a) constructing a transgenic nucleic acid construct, wherein said construct comprises nucleic acid sequences encoding:
- i) a Colla1 gene-specific regulatory element, and wherein said regulatory element is inserted into the construct at a far upstream DNAse I-hypersensitive site;
- ii) a Colla1 gene promoter;
- and
- iii) a reporter;
- b) transfecting the construct into a non-human animal capable of differentially expressing the reporter in different tissues;
- and
- c) monitoring expression of the reporter in different tissues in the non-human animal.
Dependencies are inferred from the claim text.